http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
폐경기 골다공증 여성에 있어서 Alendronate 치료에 대한 골교체의 생화학적 표지자의 평가
김기석(Kie Suck Kim),민부기(Bu Kie Min),이승필(Seung Fil Lee),김인숙(In Suk Kim),김훈영(Hun Young Kim),심재량(Jae Ryang Sim) 대한폐경학회 2000 대한폐경학회지 Vol.6 No.1
N/A Objectives: To evaluate the clinical utility of recently developed biochemical markers of bone turnover to monitor the response of osteoporotic patients to antiresorptive therapy, we compared the results of two advanced assays for markars of bone resorption and two of bone formation. Subjects and Methods: The rate of bone turnover in 37 women (mean±SD age, 58.2±4.5yr) with low boe mass and all postmenopausal women (mean±SD yr PMP, 8.3±5.2) was compared to that in 16 Premenopausal women(mean+SD age, 40.2±5.3yr) randomly selected from out-patient in our hospital and all have a normal spine bone mineral density(BMD). Perodically during the 12-month study,the level of several markers of bone turnover wen, measured. Serum osteocalcin, bone specific alkaline phosphatase mesured by RIA were used to assess bone formation. To assess bone resorption, we measured urinary excretion of Dedxypyridinoline, type l collagen cross-linked N- telopeptide, Result: All bone formation markers and all bone resorption marker were significantly increased in PMP Osteoporotic women. Under treatment with alendronate, resorption markers decreased earlier than marker of bone formation, Conclusion: This study, using biochemical markers of bone turnover, demonstrates that bone turnover is increased in PMP osteoporotic women. Alendronate treatment decreased bone turnover to the normal premenopausal range, with a steady state level reached after 1 month of therapy with 10mg for resorption markers and after 3-6 months of therapy for markers of bone formation.